SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:lup.lub.lu.se:9e7fa0b5-9011-4c6e-90bb-6f648eebfb46"
 

Search: id:"swepub:oai:lup.lub.lu.se:9e7fa0b5-9011-4c6e-90bb-6f648eebfb46" > Ponezumab in mild-t...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Landen, Jaren W.Pfizer Inc. US (author)

Ponezumab in mild-to-moderate Alzheimer's disease : Randomized phase II PET-PIB study

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • 2017-06-08
  • Wiley,2017
  • 9 s.

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:9e7fa0b5-9011-4c6e-90bb-6f648eebfb46
  • https://lup.lub.lu.se/record/9e7fa0b5-9011-4c6e-90bb-6f648eebfb46URI
  • https://doi.org/10.1016/j.trci.2017.05.003DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Introduction The safety, pharmacokinetics, and effect on peripheral and central amyloid β (Aβ) of multiple doses of ponezumab, an anti-Aβ monoclonal antibody, were characterized in subjects with mild-to-moderate Alzheimer's disease treated for 1 year. Methods Subjects were aged ≥50 years with Mini–Mental State Examination scores 16 to 26. Cohort Q was randomized to ponezumab 10 mg/kg (n = 12) or placebo (n = 6) quarterly. Cohort M was randomized to a loading dose of ponezumab 10 mg/kg or placebo, followed by monthly ponezumab 7.5 mg/kg (n = 12) or placebo (n = 6), respectively. Results Ponezumab was generally well tolerated. Plasma concentrations increased dose dependently, but cerebrospinal fluid (CSF) penetration was low. Plasma Aβ increased dose dependently with ponezumab, but CSF biomarkers, brain amyloid burden, cognition, and function were not affected. Conclusions Both ponezumab dosing schedules were generally safe and well tolerated but did not alter CSF biomarkers, brain amyloid burden, or clinical outcomes.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Andreasen, NielsKarolinska University Hospital (author)
  • Cronenberger, Carol L.Pfizer Inc. US (author)
  • Schwartz, Pamela F.Pfizer Inc. US (author)
  • Börjesson-Hanson, AnneSahlgrenska University Hospital (author)
  • Östlund, HenrikLund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups(Swepub:lu)med-hk_ (author)
  • Sattler, Catherine A.Pfizer Inc. US (author)
  • Binneman, BrendonPfizer Inc. US (author)
  • Bednar, Martin M.Pfizer Inc. US (author)
  • Pfizer Inc. USKarolinska University Hospital (creator_code:org_t)

Related titles

  • In:Alzheimer's and Dementia: Translational Research and Clinical Interventions: Wiley3:3, s. 393-4012352-8737

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view